Protagonist Therapeutics, Inc. logo

Protagonist Therapeutics, Inc.

NASDAQ:PTGX

Overview | Financials
Company Name Protagonist Therapeutics, Inc.
Symbol PTGX
Currency USD
Price 46.76
Market Cap 2,754,379,096
Dividend Yield 0%
52-week-range 14.78 - 48.89
Industry Biotechnology
Sector Healthcare
CEO Dr. Dinesh V. Patel Ph.D.
Website https://www.protagonist-inc.com

An error occurred while fetching data.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis,

Related Stocks

Sight Sciences, Inc. logo

Sight Sciences, Inc.

SGHT

5.21 USD

Akoya Biosciences, Inc. logo

Akoya Biosciences, Inc.

AKYA

2.73 USD

ADMA Biologics, Inc. logo

ADMA Biologics, Inc.

ADMA

19.37 USD

AxoGen, Inc. logo

AxoGen, Inc.

AXGN

13.95 USD

Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc.

TARS

47.3 USD

OrganiGram Holdings Inc. logo

OrganiGram Holdings Inc.

OGI

1.73 USD

Repare Therapeutics Inc. logo

Repare Therapeutics Inc.

RPTX

3.58 USD

Incannex Healthcare Limited logo

Incannex Healthcare Limited

IXHL

0.84 USD

Financials

Numbers are in millions USD

Numbers are in millions USD